Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 3/20 | 0.48 |
| ▸ | MTTP | P55157 | 10/20 | 0.46 |
| ▸ | APOB | P04114 | 9/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6499652 | 0.88 | KDR (0.48) | SMOMTTPAPOBKDR | |
| SCHEMBL6491055 | 0.80 | APOB (0.60) | SMOMTTPAPOBMCHR1NPC1 | |
| SCHEMBL6491014 | 0.79 | EIF2AK3 (0.50) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6499110 | 0.78 | EIF2AK3 (0.49) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6490739 | 0.78 | EIF2AK3 (0.49) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6490743 | 0.78 | EIF2AK3 (0.49) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6500088 | 0.77 | EIF2AK3 (0.50) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6500016 | 0.77 | APOB (0.56) | SMOMTTPAPOB | |
| SCHEMBL6489289 | 0.77 | L3MBTL1 (0.46) | KDRNPC1RAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL6493547 | 0.76 | L3MBTL1 (0.45) | KDRNPC1RAB9ASMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | DAISO CO., LTD. (JP) | 2005-02-17 | — | — | US | disclosed |
| EP-1472226-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-11-03 | — | — | EP | disclosed |
| WO-2003045921-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | APOB, APOL1, CTRB2 | SMO 2580/4885MTTP 677/4885APOB 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.